Trial Profile
A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in Children With MDR-TB With and Without HIV
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Delamanid (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Acronyms IMPAACT2005
- 15 Sep 2023 Planned End Date changed from 2 Oct 2025 to 30 Oct 2025.
- 15 Sep 2023 Planned primary completion date changed from 16 May 2024 to 30 May 2024.
- 08 Sep 2023 Planned End Date changed from 31 Mar 2027 to 2 Oct 2025.